Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: A critical review of the literature

Transplantation

Volumn 94, Issue 6, 2012, Pages 547-561

  Nashan, Björn ^a   Citterio, Franco ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Everolimus; Healing; Kidney transplantation; Sirolimus; Wound

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AGE; BODY MASS; DIABETES MELLITUS; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; INCISIONAL HERNIA; INDIVIDUALIZATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCELE; MEDICAL LITERATURE; MULTICENTER STUDY (TOPIC); OBESITY; PATIENT CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; UNITED STATES; URINARY TRACT DISEASE; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; WOUND HEALING;

EID: 84866731714     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182551021     Document Type: Review

References (84)

1. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-Transplant recipients. Transplantation 2003; 76: 172-9.
2. Tiong HY, Flechner SM, Zhou L, et al. A systematic approach to minimizing wound problems for de novo sirolimus-Treated kidney transplant recipients. Transplantation 2009; 87: 29-6.
3. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-Treated renal transplant recipients. Clin Transplant 2007; 21: 46-0.
4. Kuo JH, Wong MS, Perez RV, et al. Renal transplant wound complications in the modern era of obesity. J Surg Res 2012; 173: 21-6.
5. Mehrabi A, Fonouni H, Wente M, et al. Wound complications following kidney and liver transplantation. Clin Transplant 2006; 20(suppl 17): 9-7.
6. Kiberd B, Panek R, Clase CM, et al. The morbidity of prolonged wound drainage after kidney transplantation. J Urol 1999; 161: 146-7.
7. Humar A, Ramcharan T, Denny R, et al. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 2001; 72: 192-0.
8. Grim SA, Slover CM, Sankary H, et al. Risk factors for wound healing complications in sirolimus-Treated renal transplant recipients. Transplant Proc 2006; 38: 352-0.
9. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-Analysis of randomized trials. Transplantation 2006; 81: 123-4.
10. Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011; 12: 121-6.
11. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 112-8.
12. Merion RM, Twork AM, Rosenberg L, et al. Obesity and renal transplantation. Surg Gynecol Obstet 1991; 172: 36-7.
13. Pe'rez-Sa'ez MJ, Toledo K, Navarro MD, et al. Long-Term survival of simultaneous pancreas-kidney transplantation: influence of early posttransplantation complications. Transplant Proc 2011; 43: 216-0.
14. Seow YY, Alkari B, Dyer P, et al. Cold ischemia time, surgeon, time of day, and surgical complications. Transplantation 2004; 77: 138-6.
15. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 155-5.
16. Goel M, Flechner SM, Zhou L, et al. The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation. J Urol 2004; 171: 178-8.
17. Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation 2002; 74: 67-5.
18. Sørensen LT, Hemmingsen U, Kallehave F, et al. Risk factors for tissue and wound complications in gastrointestinal surgery. Ann Surg 2005; 241: 65-4.
19. Piffaretti G, Mariscalco G, Tozzi M, et al. Predictive factors of complications after surgical repair of iatrogenic femoral pseudoaneurysms. World J Surg 2011; 35: 91-1.
20. Riou JP, Cohen JR, Johnson H Jr. Factors influencing wound dehiscence. Am J Surg 1992; 163: 32-4.
21. Matsuda K, Hotta T, Takifuji K, et al. Long-Term comorbidity of diabetes mellitus is a risk factor for perineal wound complications after an abdominoperineal resection. Langenbecks Arch Surg 2009; 394: 6-5.
22. Karthikesalingam A, Kitcat M, Malata CM. Abdominoplasty in patients with and without pre-existing scars: a retrospective comparison. J Plast Reconstr Aesthet Surg 2011; 64: 36-9.
23. Douzdjian V, Gugliuzza KK. The impact of midline versus transverse incisions on wound complications and outcome in simultaneous pancreas-kidney transplants: a retrospective analysis. Transpl Int 1996; 9: 6-2.
24. Nanni G, Tondolo V, Citterio F, et al. Comparison of oblique versus hockey-stick surgical incision for kidney transplantation. Transplant Proc 2005; 37: 247-9.
25. Chang EI, Galvez MG, Padilla BE, et al. Ten-year retrospective analysis of incisional herniorrhaphy following renal transplantation. Arch Surg 2011; 146: 2-1.
26. Khauli RB, Stoff JS, Lovewell T, et al. Post-Transplant lymphoceles: a critical look into the risk factors, pathophysiology and management. J Urol 1993; 150: 2-2.
27. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 27-5.
28. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and fibroblast growth factor betaYstimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991; 23: 283-3.
29. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002; 16: 77-1.
30. Ekici Y, Emiroglu R, Ozdemir H, et al. Effect of rapamycin on wound healing: an experimental study. Transplant Proc 2007; 39: 120-1.
31. Simler NR, Howell DCJ, Marshall RP, et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Resp J 2002; 19: 112-4.
32. Maasilta PK, Salminen US, Lautenschlager IT, et al. Immune cells and immunosuppression in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2001: 72: 99-8.
33. Nair RV, Huang X, Shorthouse R, et al. Antiproliferative effect of rapamycin on growth factorYstimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 1997; 29: 61-4.
34. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 12-8.
35. van der Vliet JA, Willems MC, de Man BM, et al. Everolimus interferes with healing of experimental intestinal anastomoses. Transplantation 2006; 82: 147-7.
36. Willems MC, van der Vliet JA, de Man BM, et al. Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010; 18: 9-8.
37. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71: 77-1.
38. Patel V, Marsh CA, Dorsam RT, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 2011; 71: 710-3.
39. Kobayashi S, Kishimoto T, Kamata S, et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98: 72-6.
40. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin Transplant 2008; 22: 14-1.
41. Vitko S, Wlodarczyk Z, Kyllönen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006; 6: 53-1.
42. Machado PG, Felipe CR, Hanzawa NM, et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transplant 2004; 18: 2-8.
43. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 19-5.
44. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 163-3.
45. Franz S, Regeniter A, Hopfer H, et al. Tubular toxicity in sirolimusand cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010; 55: 33-5.
46. Glotz D, Charpentier B, Abramovicz D, et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 151-1.
47. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008; 85: 48-6.
48. Büchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 252-2.
49. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, et al. Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center. Transplantation 2006; 82: 153-3.
50. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipientsVan interim analysis. Am J Transplant 2005; 5: 152-9.
51. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 125-2.
52. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 107-0.
53. Groth CG, Bäckman L, Morales JM, et al. Sirolimus (rapamycin) Ybased therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 103-6.
54. Pescovitz MD, Vincenti F, Hart M, et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol 2007; 64: 75-8.
55. Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2005; 78: 153-2.
56. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 24-4.
57. Tedesco SilvaHJr, Cibrik D, Johnston T, et al. Everolimus plus reducedexposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-Transplant recipients. Am J Transplant 2010; 10: 140-1.
58. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 6-9.
59. De Vivo A, Mancuso A, Giabcobbe A, et al. Wound length and corticosteroid administration as risk factors for surgical-site complications following lymphocele section. Acta Obstet Gynecol Scand 2010; 89: 35-5.
60. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-Term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 25-2.
61. Ekberg H, Bernasconi C, Nöldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the SYMPHONY study. Nephrol Dial Transplant 2010; 25: 200-4.
62. Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010; 23: 108-4
63. Center for Drug Evaluation and Research. Application number 21-560x000. Medical Reviews. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2010/021560s000medr.pdf. Accessed December 2011.
64. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very lowexposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009: 88: 119-4.
65. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 62-6.
66. Petrova DT, Brandhorst G, Brehmer F, et al. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. Ther Drug Monit 2010; 32: 40-5.
67. Wicke C, Halliday B, Allen D, et al. Effects of steroids and retinoids on wound healing. Arch Surg 2000; 135: 126-5.
68. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11: 27-7.
69. Gaber MW, Aziz AM, Shang X, et al. Changes in abdominal wounds following treatment with sirolimus and steroids in a rat model. Transplant Proc 2006; 38: 333-1.
70. Greenblatt DY, Kelly KJ, Rajamanickam V, et al. Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2011; 18: 212-6.
71. Wahie S, Lawrence CM. Wound complications following diagnostic skin biopsies in dermatology inpatients. Arch Dermatol 2007; 143: 126-7.
72. Sandrini S, Setti G, Bossini N, et al. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy. Clin Transplant 2009; 23: 1-6.
73. Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008; 23: 70-7.
74. Kumar MSA, Heifets M, Fyfe B, et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80: 80-7.
75. Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the early use of mTOR inhibitors (sirolimus) in renal transplantation. Transplant Int 2009; 22: 68-1.
76. Smith MP, Newstead CG, Ahmad N, et al. Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation. Transplantation 2008; 85: 63-6.
77. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 256-2.
78. Matas AJ. Resolved: in minimizing kidney transplant immunosuppression, steroids should go before calcineurin inhibitors: pro. JAmSoc Nephrol 2007; 18: 302-6.
79. Fletcher F, Ain M, Jacobs R. Healing of foot ulcers in immunosuppressed renal transplant patients. Clin Orthop Relat Res 1993; (296): 3-7.
80. Scheuerlein H, Rauchfuss F, Gharbi A, et al. Laparoscopic incisional hernia repair after solid-organ transplantation. Transplant Proc 2011; 43: 178-3.
81. Pascual J, Galeano C, Celemín D, et al. Uneventful thoracic healing with everolimus after aortic valve replacement. Ann Thorac Surg 2007; 84: 27-1.
82. Altomare JF, Smith RE, Potdar S, et al. Delayed gastric ulcer healing associated with sirolimus. Transplantation 2006; 82: 43-7.
83. Molinari M, Al-Saif F, Ryan EA, et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 2005; 5: 279-9.
84. Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant 2005; 19: 25-0.